0
0
Read Time:10 Second
Biocon Limited has informed the Exchange regarding a press release dated April 21, 2026, titled “Biocon Receives Health Canada Approval of Bosaya (Denosumab) and Vevzuo (Denosumab), Biosimilars to Prolia® and Xgeva®”. |SUBJECT: Press Release
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %